Rami Elghandour, Arcellx CEO

FDA lifts par­tial hold on Ar­cel­lx’s Gilead-part­nered blood can­cer cell ther­a­py as biotech aims for 2026 launch

Ar­cel­lx’s Gilead-part­nered mul­ti­ple myelo­ma cell ther­a­py is in the clear, as the FDA has re­moved the par­tial clin­i­cal hold it placed on the CAR …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.